

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 9989)**

**POSITIVE PROFIT ALERT**  
**ANNOUNCEMENT ON THE ESTIMATED INCREASE IN PROFIT**  
**FOR THE ANNUAL RESULTS OF 2022**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the requirements of Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) for the purpose of providing shareholders of the Company (the “**Shareholders**”) and the public with the financial information of the Company. This announcement is also published in accordance with Rule 13.10B of the Listing Rules as it is also published on the Shenzhen Stock Exchange.

The following is the estimated annual results for 2022 of the Company together with its subsidiaries (the “**Group**”). The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to shareholders of the listed company or as otherwise indicated, prepared in accordance with the People's Republic of China Accounting Standards for Business Enterprises. Detailed financial information of the Group for the year ended December 31, 2022 (the “**Reporting Period**”) will be disclosed in the annual results announcement of the Company for the year ended December 31, 2022, which is expected to be published on or before March 31, 2023 in accordance with the Listing Rules.

## I. ESTIMATED RESULTS FOR THE PERIOD

1. Period to which the estimated results apply: From January 1, 2022 to December 31, 2022
2. Expected operating results:  Loss  Turnaround  Increase compared with the corresponding period  Decrease compared with the corresponding period

Items	During the Reporting Period	Corresponding period of last year
Net profit attributable to shareholders of the listed company	Earnings: RMB617.00 million to RMB773.00 million	Earnings: RMB240.79 million
	Increase as compared with the corresponding period: 156.24% to 221.03%	
Net profit after non-recurring profit or loss	Earnings: RMB622.00 million to RMB810.00 million	Earnings: RMB90.11 million
	Increase as compared with the corresponding period: 590.27% to 798.90%	
Basic earnings per share	Earnings: RMB0.4205 per share to RMB0.5268 per share	Earnings: RMB0.1641 per share

## II. COMMUNICATION WITH THE ACCOUNTING FIRM

The relevant data of this results forecast have not been pre-audited by an accounting firm. Regarding the results forecast, the Company has communicated with the accounting firm in advance and there is no disagreement among us.

### **III. REASONS FOR CHANGES IN THE RESULTS**

1. During the reporting period, against the backdrop of a complex global economic environment, the Company continued to focus on its main business and accelerated its market expansion, achieving relatively rapid growth in operating income. In terms of its Active Pharmaceutical Ingredient (API) business segment, the Company maintained its leading position in the market and continued to strengthen the support for its fast-growing finished dose pharmaceutical products business while meeting the demand of API customers' orders, which provided solid protection for the Company's heparin chain. In terms of its finished dose pharmaceutical products business segment, the Company's sales of finished dose enoxaparin sodium pharmaceutical products performed well globally, with rise in both sales revenue and market share, further solidifying the Company's strategy of transforming into a high-end finished dose pharmaceutical products industry. In terms of its Contract Development and Manufacturing Organization (CDMO) business segment, the Company not only stepped up efforts to obtain new orders, but also endeavoured to adjust the product structure and improve the overall efficiency, which resulted in an increase in both the operating income and profit of the Company's CDMO business in 2022.
2. During the reporting period, benefitting from the Company's proactive implementation and execution of global supply chain management strategy and operational efficiency enhancement strategy, the Company's profitability continued to improve. On the one hand, the orderly price adjustment of raw materials for heparin, coupled with the Company's proactive implementation of its global supply chain management strategy for raw materials, reduced the impact of price fluctuations of raw materials on the gross profit margin of the Company's heparin industry chain, and the gross profit margin of the heparin industry chain gradually rebounded. On the other hand, the Company actively adjusted its financial structure, strengthened cost control, optimized asset allocation with enhancement in both corporate financial and management strategies, thereby continuously improving operational efficiency.

#### IV. OTHER RELEVANT INFORMATION

The Company is still in the course of finalizing its consolidated financial results of the Group for the year ended December 31, 2022. The information contained in this announcement is only based on the preliminary assessment made by the Board of Directors of the Company (the “**Board**”) by reference to the Group’s unaudited consolidated management accounts and the information currently available to the Board. Regarding the results forecast, the Company has communicated with the independent auditor in advance and there is no disagreement among us. Such information has neither been confirmed nor audited by the independent auditor of the Company or the audit committee of the Board and may be subject to change. Shareholders and potential investors are advised to refer to the Company’s announcement relating to the annual results of the Group for the year ended December 31, 2022, which is expected to be published on or before March 31, 2023. **Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
January 30, 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*